A Major Study Using Daxor's BVA-100 Blood Volume Analyzer Reported at the Annual Society of Critical Care Medicine Conference
Posted on: Monday, 26 February 2007, 09:01 CST
Daxor Corporation (AMEX: DXR) -- The study entitled "Does Hematocrit Reflect Red Cell Volume when Adjusted for Plasma Volume" involved 370 patients who had a total of 689 separate blood volume measurements in the intensive care units at the Queen's Medical Center in Honolulu, Hawaii. Senior authors of the study were Dr. Kurt Edwards and Mihae Yu, et al., from the University of Hawaii. This is the largest series in medical history where hematocrits were compared to direct blood volume measurement.
The study compared the hematocrit, which is the proportion of a volume of a blood sample that is red blood cells to the result obtained when actually measuring the volume of blood in a patient. The hematocrit is the standard test used to estimate the quantity of blood in a person and is used in hundreds of thousands of clinical decisions annually with respect to whether or not to transfuse a patient. Patients in the study were critically ill; 36% had severe sepsis and/or shock; 31.2% were trauma patients; 10% were congestive heart failure patients; and 14% were acute kidney failure patients. In 28 (5% of the cases), patients had lost more than 40% of their red blood cells and still had a hematocrit of 30 or better, indicating no need for transfusions. Under usual circumstances they would have been denied a transfusion. In 12 (2% of the patients), there was a red cell deficit of less than 10% with a hematocrit less than 30. These were patients who clearly did not need transfusions; yet, under the usual circumstances, would have been transfused. The authors concluded that direct measurement of blood volume provides a more specific guide to red cell transfusion than the hematocrit test which does not measure volume directly. Patients may be denied transfusions who would benefit from transfusions, and some patients may be transfused who do not need a transfusion.
Daxor Corporation manufactures and markets the BVA-100, a semi-automated Blood Volume Analyzer. The BVA-100 is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website www.Daxor.com.
Contact Information: Stephen Feldschuh Chief Operating Officer 212-330-8515 Contact via http://www.marketwire.com/mw/emailprcntct?id=2C154BA360501710 or Diane Meegan Investor Relations 212-330-8512 Contact via http://www.marketwire.com/mw/emailprcntct?id=0FAC398C3B737256
SOURCE: Daxor Corp.
Source: MARKET WIRE
Related Articles
- Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans
- Patients Issue Summer Call to Action: 'We Need You to Donate Blood -- NOW'
- Photo: Levemir(R) Once-Daily Substantially Lowered Average Blood Sugar Levels of Patients with Type 2 Diabetes in TITRATE(R) Study
- Elan and Transition Therapeutics Achieve Patient Enrollment Target in Phase 2 Clinical Study of ELND005 (AZD-103) in Alzheimer's Disease
- First Patient Enrolled in RAPID MI-ICE Study Employing InnerCool's Endovascular Temperature Modulation Therapy for Heart Attack
- Spectrum Pharmaceuticals Announces Successful Completion of Patient Accrual in Its EOquin(R) Pilot Study, Prior to Initiating Phase 3 Studies in the U.S.
- Red Cross says needs 40,000 Katrina volunteers
- Infections of Febrile Neutropenic Patients in Malignant Hematological Diseases (Second Study Period)
- Patient Deaths Have Declined in Cancer Studies Since 1991
- Antidepressant Study Needs Mexican Volunteers
 |
 |
User Comments (0)
RSS Feeds